[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI0956034T1 - Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin - Google Patents

Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin

Info

Publication number
SI0956034T1
SI0956034T1 SI9730389T SI9730389T SI0956034T1 SI 0956034 T1 SI0956034 T1 SI 0956034T1 SI 9730389 T SI9730389 T SI 9730389T SI 9730389 T SI9730389 T SI 9730389T SI 0956034 T1 SI0956034 T1 SI 0956034T1
Authority
SI
Slovenia
Prior art keywords
cyclosporin
rapamycin
autoimmune
hydroxyethyl
treatment
Prior art date
Application number
SI9730389T
Other languages
Slovenian (sl)
Inventor
Gerhard Zenke
Hendrik J. Schuurman
Barbara Haeberlin
Armin Meinzer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615942.1A external-priority patent/GB9615942D0/en
Priority claimed from GBGB9705684.0A external-priority patent/GB9705684D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from EP97937526A external-priority patent/EP0956034B1/en
Publication of SI0956034T1 publication Critical patent/SI0956034T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SI9730389T 1996-07-30 1997-07-29 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin SI0956034T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9615942.1A GB9615942D0 (en) 1996-07-30 1996-07-30 Organic compounds
GBGB9705684.0A GB9705684D0 (en) 1997-03-18 1997-03-18 Organic compounds
EP97937526A EP0956034B1 (en) 1996-07-30 1997-07-29 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin
PCT/EP1997/004123 WO1998004279A1 (en) 1996-07-30 1997-07-29 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin

Publications (1)

Publication Number Publication Date
SI0956034T1 true SI0956034T1 (en) 2002-12-31

Family

ID=27238941

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730389T SI0956034T1 (en) 1996-07-30 1997-07-29 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin

Country Status (1)

Country Link
SI (1) SI0956034T1 (en)

Similar Documents

Publication Publication Date Title
NZ333657A (en) A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
AU5219198A (en) Method to prevent transplant rejection
HK1010853A1 (en) Stent and the fabrication method thereof
IL107190A (en) Immunosuppressive pharmaceutical compositions comprising rapamycin carbamates and certain such novel compounds
AU3121797A (en) Intraluminal stent
AU5355598A (en) Variable flexibility stent
WO1998002441A3 (en) Non immunosuppressive antifungal rapalogs
HUP9902922A3 (en) Plant immunization compositions
ZA978725B (en) Herbicidal and plant growth regulant compositions and the use thereof
HUP9701038A3 (en) Equipment for storing and total emptyng fats
IL135935A0 (en) Shaped polyurethane bodies for use as implants
EP0876157A4 (en) Methods and compositions for passive immunotherapy
DE59711381D1 (en) Stent
ZA976110B (en) Elastomers processes for their manufacture and articles made from these elastomers
SI0956034T1 (en) Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin
HUP9801123A3 (en) Method to prevent transplant rejection
IL121931A (en) Pharmaceutical compositions for preventing allograft rejection
GB9619633D0 (en) Recombinant plant cells
DE59710344D1 (en) Stent
AU4371296A (en) Compositions and methods for preventing and treating allograft rejection
EP0882815A4 (en) Electrochemical plant
GB9622977D0 (en) Plant support
AU128266S (en) Shark protective cage
GB9616082D0 (en) Prosthetic support
SI0917460T1 (en) Cyclosporin formulation